Business
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYN...
About this update from Mynd Life Sciences Inc
[{"type":"text","content":"MYND Life Sciences Announces Strategic Debt Reduction and New Board Member AppointmentVancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (\"MYND\" or the \"Company\"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial position and governance. These moves demonstrate a strong commitment to the company's vision and strategic plan to commercialize a diagnostic biomarker test for depression which is being initially developed for the purpose of diagnosing and monitoring those with major depressive disorder (MDD). Debt ReductionAs part of our ongoing commitment to financial health and operational efficiency, MYND Life Sciences has successfully removed $800,619.65 (CDN) in Loan and Officer deferred salary debt and has been converted into shares of MYND Life Sciences. This conversion is intended to align the interests of the company's leadership with its shareholders and to demonstrate a buy-in to MYND's vision and strategic plan. \"We believe this move reflects our unwavering commitment to the company's future and our confidence in our strategic direction in developing a depression biomarker test,\" said Colin Campbell, CEO. \"By converting our debt into equity, we are not only reinforcing our belief in MYND's long-term success but also aligning our interests more closely with those of our shareholders.\" New Strategic Board Member MYND Life Sciences is pleased to announce the appointment of Lana Hoogenboom to its Board of Directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs. \"We are thrilled to welcome Lana Hoogenboom to our Board of Directors,\" said Colin Campbell, CEO of MYND Life Sciences. \"Lana's extensive experience and strategic insigh...